The Mark Foundation Awards First Grant to Seattle Biotech Company

In September 2017, The Mark Foundation announced its inaugural award to Seattle-based oncology company, Presage Biosciences. The Foundation provided support for a one-year feasibility study employing CIVO™ technology, Presage’s novel drug development platform which aims to assess drugs and drug combinations directly in patient tumors. Foundation CEO, Dr. Michele Cleary remarked, “It is with great confidence that our support of this endeavor will ultimately result in better options for patients with cancer.”

Read official press release here.